APA (7th ed.) Citation

A, M., C, R., G, d. M., D, R., MR, C., M, D., . . . A, C. (2023). Sodium-glucose cotransporter-2 (SGLT2) inhibitors and the reporting of falls and fractures: An european pharmacovigilance analysis. Frontiers in pharmacology, 14, 1245642. https://doi.org/10.3389/fphar.2023.1245642

Chicago Style (17th ed.) Citation

A, Mascolo, et al. "Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors and the Reporting of Falls and Fractures: An European Pharmacovigilance Analysis." Frontiers in Pharmacology 14 (2023): 1245642. https://doi.org/10.3389/fphar.2023.1245642.

MLA (9th ed.) Citation

A, Mascolo, et al. "Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors and the Reporting of Falls and Fractures: An European Pharmacovigilance Analysis." Frontiers in Pharmacology, vol. 14, 2023, p. 1245642, https://doi.org/10.3389/fphar.2023.1245642.